News

Winston-Salem Journal2h
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...